Bayer Healthcare Pharmaceuticals INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$73Mgeneral payments (2019-2025)
$1.7Mresearch payments (2019-2025)
157,776clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
- Kerendia $1,438 associated (2023-2025)
- Kyleena $777 associated (2023-2025)
- Mirena $762 associated (2023-2025)
- Nubeqa $419 associated (2023-2025)
- Xofigo $249 associated (2023-2025)
- Adempas $134 associated (2023-2025)
- Skyla $50.21 associated (2023-2025)
- Vitrakvi $47.12 associated (2023-2025)
- Kovaltry $40.64 associated (2023-2025)
- Jivi $40.64 associated (2023-2025)
- Stivarga $20.45 associated (2023-2025)
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Dwight Koeberl | Durham, NC | Pediatrics | $1,005,900.56 |
| David Muram | Indianapolis, IN | $799,417.50 | |
| Bruce Blazar | Minneapolis, MN | Pediatric Hematology-Oncology | $634,975.60 |
| Roger Hajjar | New York, NY | Cardiovascular Disease | $619,683.10 |
| Priya Kishnani | Durham, NC | Pediatrics | $379,189.17 |
| Ramon Mendez | Woodbridge, VA | Nephrology (Internal Medicine) | $379,066.47 |
| Rajiv Agarwal | Indianapolis, IN | Nephrology (Internal Medicine) | $344,347.46 |
| Neal Shore | Myrtle Beach, SC | Urology | $329,985.66 |
| Ronald Korn | Scottsdale, AZ | Diagnostic Radiology | $326,196.00 |
| Biff Palmer | Dallas, TX | Nephrology (Internal Medicine) | $317,338.45 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.